Unbiased Analysis of Today's Healthcare Issues
ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…
Three panels. One great city. Can’t wait for the conversations at ISPOR 2024 in Montréal. GCEA: Where do we go from here? (14 May, 5-6pm) Should we finally rethink the 3% discount rate? (15 May, 3:15-4:15pm) How can HEOR support providers in value-based care? (16 May, 10-11am) I’ll be diving into all three — including teaming…
That is the title of a new FTI Consulting white paper co-authored with Kyi-Sin Than. The abstract is below. In October 2023, ICER released a special assessment aimed at influencing CMS drug price negotiations for two direct-acting oral anticoagulants (DOACs) selected in the first round of Inflation Reduction Act (IRA) price negotiations in 2024: Eliquis®…
That is the title of a new paper with Shanshan Wang, Jaehong Kim, and Slaven Sikirica that has the subtitle “Budget impact analysis from the US payer perspective.” That abstract is below: BACKGROUND:Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus. These patients face…
That is the title of a paper recently published in AJMC with co-authors Suhail Thahir, Alexa Klimchak, Ivana Audhya, Lauren Sedita, and John A. Romley. The abstract is below. Objectives: To quantify the magnitude of altruism value as applied to a hypothetical new treatment for a rare, severe pediatric disease: Duchenne muscular dystrophy (DMD). Study Design: Prospective…
Today, the American Cancer Society’s Cancer Action Network released a report titled “Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival.” The empirical analysis was conducted by myself and some colleagues at FTI Consulting (Shanshan Wang, Shurui Zhang, Citseko Staples Miller, and Sophia Mildred Setterberg). An…
Here is the list of my papers that were published in 2024. Manuscripts were published in Value in Health, BMJ Open, Journal of Comparative Effectiveness Research, Forum for Health Economics and Policy, Annals of the American Thoracic Society and others. Links to all papers are below. Clayton D, Shafrin J, Yen GP, Geevarghese L, Shi…
That is the title of an interview with me in The Evidence Base out today with the subtitle Introducing generalized cost effectiveness analysis for a comprehensive value assessment. Below is an excerpt: What is this paper about? What is new in this paper?Our recent publication presents a comprehensive framework for evaluating the societal value of health technologies,…
That is my recent paper with co-authors Shanshan Wang, Jason Shafrin, and Kirk Kerr in BMJ Open. The abstract is below: Objective To estimate the health economic value of postdischarge oral nutrition supplement (ONS) consumption among elderly adults who were malnourished during hospitalisation. Design A cost-effectiveness model was developed from a US payer perspective based on a…
I will be presenting two panels at ISPOR Europe 2024 in Barcelona next week! This year’s conference theme centers on the importance of scientific evidence in understanding and improving the health and well-being of people across the globe. Panel 1: Broader Value Elements: Methods to Quantify Each and Their Relevance for European Markets Monday, Nov…